Kiniksa Pharmaceuticals, Ltd. (KNSA)
| Market Cap | 1.43B |
| Revenue (ttm) | 301.77M |
| Net Income (ttm) | 8.65M |
| Shares Out | 70.94M |
| EPS (ttm) | 0.12 |
| PE Ratio | 168.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 326,534 |
| Open | 20.27 |
| Previous Close | 20.26 |
| Day's Range | 20.00 - 20.38 |
| 52-Week Range | 13.02 - 22.09 |
| Beta | 0.30 |
| Analysts | Strong Buy |
| Price Target | 30.20 (+49.58%) |
| Earnings Date | Apr 23, 2024 |
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter... [Read more]
Financial Performance
In 2023, KNSA's revenue was $270.26 million, an increase of 22.74% compared to the previous year's $220.18 million. Earnings were $14.08 million, a decrease of -92.32%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $30.2, which is an increase of 49.58% from the latest price.
News
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2...
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abipr...
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:...
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
– Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart developmen...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 a...
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, J...
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8...
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the m...
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30...
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual G...
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growt...
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at...
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, J...
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities ...
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual Hea...
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at ...
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow He...
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
– ARCALYST ® (rilonacept) net revenue of $27.0 million in Q2 2022 –